MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

Search

Pacific Biosciences of California Inc

Geschlossen

BrancheGesundheitswesen

1.38 -6.76

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.36

Max

1.49

Schlüsselkennzahlen

By Trading Economics

Einkommen

-428M

-426M

Verkäufe

-2.1M

37M

Gewinnspanne

-1,146.812

Angestellte

575

EBITDA

-420M

-403M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+46.31% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

99M

438M

Vorheriger Eröffnungskurs

8.14

Vorheriger Schlusskurs

1.38

Nachrichtenstimmung

By Acuity

64%

36%

335 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Pacific Biosciences of California Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Juli 2025, 23:34 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17. Juli 2025, 21:14 UTC

Akquisitionen, Fusionen, Übernahmen

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17. Juli 2025, 21:04 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17. Juli 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17. Juli 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17. Juli 2025, 22:47 UTC

Akquisitionen, Fusionen, Übernahmen

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17. Juli 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17. Juli 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17. Juli 2025, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17. Juli 2025, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17. Juli 2025, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17. Juli 2025, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17. Juli 2025, 22:30 UTC

Market Talk
Ergebnisse

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17. Juli 2025, 22:20 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

17. Juli 2025, 22:20 UTC

Market Talk
Ergebnisse

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17. Juli 2025, 22:04 UTC

Market Talk
Ergebnisse

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17. Juli 2025, 22:03 UTC

Akquisitionen, Fusionen, Übernahmen

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17. Juli 2025, 21:58 UTC

Market Talk
Ergebnisse

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17. Juli 2025, 21:57 UTC

Ergebnisse

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17. Juli 2025, 21:47 UTC

Ergebnisse

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17. Juli 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Juli 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17. Juli 2025, 21:38 UTC

Akquisitionen, Fusionen, Übernahmen

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17. Juli 2025, 21:22 UTC

Akquisitionen, Fusionen, Übernahmen

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17. Juli 2025, 21:05 UTC

Ergebnisse

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17. Juli 2025, 21:04 UTC

Akquisitionen, Fusionen, Übernahmen

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17. Juli 2025, 21:02 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17. Juli 2025, 20:59 UTC

Akquisitionen, Fusionen, Übernahmen

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

17. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Pacific Biosciences of California Inc Prognose

Kursziel

By TipRanks

46.31% Vorteil

12-Monats-Prognose

Durchschnitt 2.18 USD  46.31%

Hoch 3 USD

Tief 1.25 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pacific Biosciences of California Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

1.13 / N/AUnterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

335 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.